Skip to content

Author

K. Jamuna

We have 4 of 27 papers

We haven’t gathered this author’s papers yet. Follow them and we’ll fetch their work.

Not the right person? Other researchers publish under this name.

Open access Oct 2026

Metagenomic Analysis of the Oral Microbiome in Patients with Head and Neck Squamous Cell Carcinoma: A Case-Control Study

Head and neck squamous cell carcinoma patients showed considerable changes in oral microbial profile as compared to the healthy subjects, and the functional annotation revealed enrichment of pathways related to inflammation in the HNSCC samples.

Niyati V. Thakkar, Anisha Chaudhary, Smiral Gameti et al. · 0 citations
Review Oct 2026

Engineering smart polymeric lipid nanoparticles for breast cancer: The convergence of AI and medical personalization to enhance efficacy and safety.

Breast Cancer (BC) continues to be a predominant cause of cancer-related death globally, with clinical therapy impeded by off-target toxicity and limited therapeutic windows of traditional chemotherapeutics, especially across various molecular subtypes. This study critically assesses the integration of advanced nanocar...

Usamah Sayed, Diyora Azamova, A. Abdulqader et al. · 0 citations
Review Open access Sep 2026

Viral exploitation of p300/CBP at the virus-cancer interface: Chromatin regulation, oncogenesis, immune evasion, and therapeutic targeting.

The transcriptional coactivators p300 and CREB-binding protein (CBP) integrate chromatin remodeling, enhancer activity, lysine acetylation, immune signaling, and tumor-suppressor control, making them recurrent targets of viral proteins. This narrative review examines p300/CBP at the virus-cancer interface, prioritizing...

A. Atoom, J. Rizaev, D. Polatova et al. · 0 citations
Review Open access Sep 2026

Oncolytic virotherapy at the tumor microenvironment-CAR Therapy interface: Mechanisms, clinical translation, and future directions.

Oncolytic virotherapy has evolved from a tumor-selective cytolytic strategy into a programmable immunotherapeutic platform that reshapes the tumor microenvironment (TME). Oncolytic viruses (OVs) selectively infect malignant cells, induce immunogenic cell death, release tumor antigens, and activate innate and adaptive i...

A. Atoom, J. Rizaev, D. Polatova et al. · 0 citations

We use cookies to run the site and, with your consent, for analytics and to show ads. See our Cookie Policy.